High IL-6 and CCL2 levels frequently correlate with worse clinical outcomes, reflecting a synergy among TANs, tumor cells, and other suppressive immune populations that ultimately restrict T-cell-mediated clearance. The gene discussed is CCL2; the disease is neoplasm.